Imugene Ltd IUGNF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.07
- Day Range
- $0.07–0.08
- 52-Week Range
- $0.06–0.31
- Bid/Ask
- $0.01 / $0.19
- Shares Outstanding
- 498.09M
- Market Cap
- $31.87M
- Volume/Avg
- 10,594 / 23,690
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Imugene Ltd is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 5
- Website
- https://www.imugene.com
Valuation
|
Metric
|
IUGNF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.86 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
IUGNF
|
|---|---|
Quick Ratio | 1.60 |
Current Ratio | 1.78 |
Interest Coverage | — |
Quick Ratio
IUGNF
Profitability
|
Metric
|
IUGNF
|
|---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
IUGNF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|^G##TS! | LOCK|>&<^ | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|q@mKn# | LOCK|q>#q@ | $83B | |||
| argenx SE ADR
ARGX
| LOCK|!TF%vCt | LOCK|c! | $53B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|>%yRzc?% | LOCK|Fr>? | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|fr%Z&&$ | LOCK|<?! | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|gcP&<# | LOCK|F??nj | $31B | |||
| Moderna Inc
MRNA
| LOCK|Hr?M>! | LOCK|L^ | $25B | |||
| Incyte Corp
INCY
| LOCK|k&ZV^# | LOCK|#Yc | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|?&ZF@$ | LOCK|Lg | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|<c%^F< | LOCK|%l | $16B |
United States